Advertisement

Capsule-Delivered Fecal Microbiota Transplant Is Safe and Well Tolerated in Patients with Ulcerative Colitis

  • Elizabeth Adler
  • Adam Tabaa
  • Zain Kassam
  • Martin Zydek
  • Jonathan Terdiman
  • Najwa El-NachefEmail author
Brief Report

Introduction

Fecal microbiota transplantation (FMT) has emerged as a potential therapy for ulcerative colitis (UC). Several randomized, placebo-controlled trials have shown promise for FMT to induce remission in active UC with lower gastrointestinal administration (colonoscopy/enema) followed by frequent enema maintenance [1]. Clinical remission rates appear higher with maintenance dosing in contrast to a single administration [2, 3]; however, FMT enemas may be burdensome for long-term therapy, and FMT delivered by capsules (cap-FMT) is preferred by patients [4]. Although single-dose administration of cap-FMT is safe for the prevention of recurrent C. difficile infection (rCDI) in those with underlying inflammatory bowel disease (IBD) [5, 6], it is unknown whether frequent maintenance dosing of cap-FMT is safe and well tolerated in UC patients. Accordingly, we aimed to investigate the safety and tolerability of cap-FMT in UC patients as a maintenance regimen following FMT via...

Notes

Acknowledgment

Our study was funded by an Anonymous Philanthropic Gift.

Compliance with ethical standards

Conflict of interest

ZK is an employee/shareholder of Finch Therapeutics. No other relevant disclosures or financial conflicts of interest.

References

  1. 1.
    Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23:1702–1709.  https://doi.org/10.1097/MIB.0000000000001228.CrossRefGoogle Scholar
  2. 2.
    Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017;11:1180–1199.  https://doi.org/10.1093/ecco-jcc/jjx063.CrossRefGoogle Scholar
  3. 3.
    Jacob V, Crawford C, Cohen-Mekelburg S, et al. Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis. Inflamm Bowel Dis. 2017;23:903–911.  https://doi.org/10.1097/MIB.0000000000001132.CrossRefGoogle Scholar
  4. 4.
    Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985–1993.  https://doi.org/10.1001/jama.2017.17077.CrossRefGoogle Scholar
  5. 5.
    Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal microbiota transplantation for recurrent clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol. 2017;15:597–599.  https://doi.org/10.1016/j.cgh.2016.11.028.CrossRefGoogle Scholar
  6. 6.
    Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:2402–2409.  https://doi.org/10.1097/MIB.0000000000000908.CrossRefGoogle Scholar
  7. 7.
    El-Nachef N, Piceno YM, Kassam Z, et al. The role of fecal microbiota transplantation in ulcerative colitis and Crohn’s disease: results from a parallel inflammatory bowel disease cohort study. Gastroenterology. 2017;152:S1008.  https://doi.org/10.1016/S0016-5085(17)33420-0.Google Scholar
  8. 8.
    Burns L, Dubois N, Smith M, et al. 499 Donor recruitment and eligibility for fecal microbiota transplantation: results from an international public stool bank—gastroenterology. Gastroenterology. 2015;148:S-96–S-97.CrossRefGoogle Scholar
  9. 9.
    Dubois N, Ling K, Osman M, et al. Prospective assessment of donor eligibility for fecal microbiota transplantation at a public stool bank: results from the evaluation of 1387 candidate donors. Open Forum Infect Dis. 2015;.  https://doi.org/10.1093/ofid/ofv133.678.Google Scholar
  10. 10.
    Kassam Z, Mendolia G, Vo E, et al. Microbial emulsion matrices: a novel method to produce stable, orally available capsules for fecal microbiota transplantation to treatClostridium difficile. Am J Gastroenterol. 2015;110:S568–S569.Google Scholar
  11. 11.
    Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.  https://doi.org/10.1002/ibd.20520.CrossRefGoogle Scholar
  12. 12.
    Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.  https://doi.org/10.1016/S0140-6736(17)30182-4.CrossRefGoogle Scholar
  13. 13.
    Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:109.e6.  https://doi.org/10.1053/j.gastro.2015.04.001.Google Scholar
  14. 14.
    Cojocariu C, Stanciu C, Stoica O, et al. Clostridium difficile infection and inflammatory bowel disease. Turk J Gastroenterol. 2014;25:603–610.  https://doi.org/10.5152/tjg.2014.14054.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Elizabeth Adler
    • 1
  • Adam Tabaa
    • 1
  • Zain Kassam
    • 3
  • Martin Zydek
    • 2
  • Jonathan Terdiman
    • 2
  • Najwa El-Nachef
    • 2
    Email author
  1. 1.Department of MedicineUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Division of Gastroenterology, Department of MedicineUniversity of California, San FranciscoSan FranciscoUSA
  3. 3.Finch TherapeuticsSomervilleUSA

Personalised recommendations